▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2391 by analyst upside · 2026-09-26
VCYT
Veracyte, Inc.
Healthcare · Market Cap $4B · P/E 32.5x
ANALYST PRICE TARGET
+28.6%
implied upside to consensus target
Current Price $45.43
Consensus Target $58.42
Bull Target $70.0
Bear Target $44.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
1
Sell
1
52-Week Low $29.45
52-Week High $60.91
YTD Return +7.2%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) 32.5x
Forward P/E 23.3x
EPS (TTM) $1.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $562M
Profit Margin 20.4%
52-WEEK RANGE
52-Week Low $29.45
52-Week High $60.91
Current Price $45.43
Bear Target $44.0
Bull Target $70.0
● Now $45.43 ● Target $58.42
TRADING DATA
Avg Volume 1.4M
YTD Return +7.2%
Analyst Count 12
Consensus Buy
Upside to Target +28.6%
Last Updated 2026-09-26

ANALYST SUMMARY

Veracyte, Inc. (VCYT) is currently trading at $45.43 with a Wall Street consensus price target of $58.42, implying potential upside of 28.6% over the next 12 months. 12 analysts currently cover VCYT, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $70.0, while the most cautious has a target of $44.0.

VCYT operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 7.2% year-to-date and is currently trading near the upper end of its 52-week range of $29.45 – $60.91.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VCYT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Freedom Capital Markets - Reiterated
Buy → Buy 2026-09-15 Building track record
UBS - Reiterated
Buy → Buy 2026-09-09 33% win rate (6 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-04 14% win rate (7 calls)
Stephens & Co. - Reiterated
Overweight → Overweight 2026-08-04 Building track record
Morgan Stanley - Reiterated
Underweight → Underweight 2026-08-04 Building track record
Canaccord Genuity - Reiterated
Hold → Hold 2026-08-03 Building track record
Needham - Reiterated
Buy → Buy 2026-07-31 20% win rate (5 calls)
Needham - Reiterated
Buy → Buy 2026-07-30 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
20/30
Consensus clarity
19/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →